RhumbLine Advisers
BLCM

RhumbLine Advisers’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

RhumbLine Advisers’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,863
Closed -$535K – 3024
2019
Q1 		$535K Sell
15,863
-543
-3% -$18.1K ﹤0.01% 2308
2018
Q4 		$479K Buy
16,406
+12,754
+349% +$566K ﹤0.01% 2316
2018
Q3 		$225K Sell
3,652
-10,197
-74% -$690K ﹤0.01% 2672
2018
Q2 		$1.02M Buy
13,849
+11,371
+459% +$886K ﹤0.01% 2001
2018
Q1 		$163K Sell
2,478
-77
-3% -$5.81K ﹤0.01% 2648
2017
Q4 		$215K Sell
2,555
-518
-17% -$50.8K ﹤0.01% 2594
2017
Q3 		$355K Buy
3,073
+6
+0.2% +$631 ﹤0.01% 2490
2017
Q2 		$358K Buy
3,067
+725
+31% +$90K ﹤0.01% 2468
2017
Q1 		$289K Buy
2,342
+56
+2% +$7.33K ﹤0.01% 2521
2016
Q4 		$311K Buy
2,286
+337
+17% +$59.8K ﹤0.01% 2475
2016
Q3 		$388K Buy
1,949
+126
+7% +$21.7K ﹤0.01% 2350
2016
Q2 		$236K Buy
+1,823
New +$203K ﹤0.01% 2660

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers's BLCM Position: Q2 2019 in Review

RhumbLine Advisers sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 15,863 shares — an estimated $535K sold.

RhumbLine Advisers first reported a position in BLCM in Q2 2016 and held it in 12 quarters. The position peaked at $1.02M in Q2 2018. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

  • RhumbLine Advisers reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • RhumbLine Advisers sold 15,863 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $535K.
  • RhumbLine Advisers first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2016 and held it in 12 quarters.
  • RhumbLine Advisers's Bellicum Pharmaceuticals, Inc. position peaked at $1.02M in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.